Page 15 - Pharma Companies

Glenmark Pharma gets US health regulator nod for inhalation product

Glenmark Pharma said it received approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market

How Biological E could emerge as game changer in India's vaccine race

Company scales up its ambition after government advanced it Rs 1,500 crore for 300 million doses of its vaccine candidate.

Hope to launch diabetic NCE by next financial year: Torrent Pharma's Mehta

We would also look into distribution opportunities to bring some of these products into the market, said Mehta

Bharat Biotech, Ocugen extend agreement to market Covaxin in Canada

Phase 3 analysis data to be submitted to WHO soon for EUL

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The medicines are a therapeutic equivalent of Banzel®

Moderna says its Covid-19 vaccine is up to 100% effective in teens

Company will submit data for regulatory authorisation in early June

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021. The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added. For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said. The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added. Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.

Natco starts phase-3 trials of Molnupiravir capsules for Covid-19 treatment

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild COVID-19.

Five pharmaceutical companies get approval to make black fungus drug

These developments come amid fast spread of the disease in various states and shortage of drugs to treat them.

Retail investors miss rally in Gland Pharma; stock up 118% over IPO price

At the time of its IPO, retail investors bid for only 24 per cent or 0.24 times of the shares set aside for them

More pharma firms should be allowed to make vaccine: Nitin Gadkari

Union Minister Nitin Gadkari on Tuesday suggested that more pharma companies should be allowed to make the COVID-19 vaccine in the country during the pandemic to scale up production.

Additional 45,000 vials of tocilizumab allocated to states: Gowda

Union Minister Sadananda Gowda on Tuesday said additional 45,000 vials of tocilizumab, used for treatment of Covid-19, have been allocated to states and union territories to meet the increased demand.

FabiFlu numero uno in Indian pharma market, show April sales data

With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore

After just Rs 18,000 cr profits in a decade, Serum, Bharat Biotech may earn big with Covid

For both companies, the pandemic presents a once-in-a-lifetime opportunity to earn hundreds of crores of rupees that could be ploughed back to fund further research and capacity expansion

Pricing pressure in US market to impact margins of pharma companies

Lack of new launches due to inspection delays, intensifying competition key headwinds

Morepen Laboratories rallies 17% in two days on fundraising plans

Morepen Laboratories board approved the issue of up to 5 crore equity shares to Liquid Holdings, an entity belonging to the promoter group of the company, at a price of Rs 38 per equity share

Private sector looking to pool demand for Covid vaccines procurement

Private sector in India is looking to pool their demand for effective procurement of vaccines to ensure uninterrupted access to the lifesaving vaccines, healthcare and industry federations said

Prioritise country first, PM Modi tells Covid-19 vaccine makers

"He has asked the industry to prioritise deliveries to meet the country's needs first and then focus on global supplies," said a person in the know, who did not wish to be named.

Covid-19: Remdesivir output to be doubled to 7.4 mn doses by April-end

18 new sites get DCGI consent to make antiviral used for treating Covid-19

Covid-19 vaccination: Too early to say if booster dose needed, say experts

Pfizer CEO has said a 3rd booster shot likely within a year of vaccination